Intrinsic Heart Rate

PreclinicalSmall molecule

Intrinsic Heart Rate is one of 20 small molecule programs targeting Orthostatic Intolerance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic IntoleranceActive, not recruiting

Orthostatic IntolerancePreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Orthostatic Intolerance

#DrugCompanyPhaseTrials

Corlanor

Northera

Prometrium

Giapreza

LLa Jolla Pharmaceutical Company

Proamatine

2 6

Isordil

AstraZeneca

Phase 2

1 7

Namenda

AbbVie

Phase 2

1 8

Diamox

Teva

Phase 2

1 9

Strattera

MMap77

Phase 2

2 10

Indocin

CCosette Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

N/AActive, not recruiting

Orthostatic Intolerance

NCT00608725

Clinical

Trials by Indication[1]

Orthostatic Intolerance1 trial

Pathophysiology of Orthostatic Intolerance

Active, not recruiting·SSatish R. Raj·N/A·NCT00608725·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intrinsic Heart Rate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrinsic Heart Rate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrinsic Heart Rate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Satish R. Raj company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSatish R. Raj

Intrinsic Heart Rate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Orthostatic Intolerance1 trial

References

Drug Info

Quick Facts

Related News